miR-135b在消化系统恶性肿瘤中的研究现状

Research status of miR-135b in malignant tumors of the digestive system

微小RNA(microRNA、miRNA)是一类内源性、单链、短而高度保守的非编码RNA。miR-135b作为miRNA中的一员,在消化系统恶性肿瘤中异常表达。其作用机制涉及多种靶基因,通过调控细胞增殖、转移、耐药等参与肿瘤的发生和发展。miR-135b的高表达与患者预后不良和生存率下降相关联。作为潜在的生物标志物,miR-135b可能有助于消化系统恶性肿瘤的诊断、预后评估和治疗监测。因此,miR-135b及其调控的通路可能成为未来治疗的靶点,为肿瘤患者的治疗和管理提供新的思路。

MicroRNAs(microRNAs,miRNAs)are a class of endogenous,single-stranded,short and highly conserved non-coding RNAs.miR-135b,as a member of miRNAs,is aberrantly expressed in digestive malignancies.Its mechanism of action involves a variety of target genes and participates in tumorigenesis and development by regulating cell proliferation,metastasis,and drug resistance.Clinical studies have shown that high expression of miR-135b is associated with poor patient prognosis and decreased survival.As a potential biomarker,miR-135b may be useful in the diagnosis,prognostic assessment,and therapeutic monitoring of malignant tumors of the digestive system.Therefore,miR-135b and its regulated pathways may become future therapeutic targets and provide new ideas for the treatment and management of tumor patients.